By Robert King
A new advisory from the U.S. surgeon general is pressing for stakeholders to alleviate healthcare worker burnout by reducing administrative and other burdens and improve access to mental health services.
read more
By Nick Paul Taylor
BridgeBio Pharma is digging in for a prolonged bear market. Since suffering a phase 3 flop late last year, the biotech has taken a series of steps to extend its cash runway, reflecting its CEO’s belief that markets could “stay pretty bad up until the end of next year”.
read more
By Andrea Park
Diabetes devicemakers Dexcom and Insulet have already aligned their product lines—with Insulet’s Omnipod insulin pumps designed to be used alongside Dexcom’s continuous glucose monitors—and soon that may become much more permanent.
read more
By Fraiser Kansteiner
Stéphane Bancel, who joined Moderna back in 2013, is cashing out his original stock options in the company for charity, the biotech’s helmsman said Tuesday. All told, Bancel expects the move to yield a donation of about $355 million, after some $280 million in state and federal tax payments.
read more
By Annalee Armstrong
Five months after Pfizer bought Arena, the team has delivered: Etrasimod, the immuno-inflammatory disease therapy that attracted the buyout, has been linked to a 27% remission rate in patients with ulcerative colitis in a phase 3 clinical trial.
read more
By Anastassia Gliadkovskaya
The group plans to advocate for improved access to care through digital health innovations and to be a hub of resources on the importance of digital health equity.
read more
By Conor Hale
Biopsy results from Illumina's TruSight Oncology Comprehensive test can now be used to identify patients with any solid tumors that harbor NTRK gene mutations.
read more
By Nick Paul Taylor
SpringWorks Therapeutics is bouncing to the FDA. With a phase 3 desmoid tumor trial hitting its primary and secondary endpoints, the Pfizer spinout is planning to seek approval for nirogacestat in the second half of the year.
read more
By Zoey Becker
In the last year of Johnson & Johnson's Stelara patent, companies are lining up to produce biosimilars. Alvotech, already armed with a promising Humira biosimilar in its pipeline, found therapeutic equivalence between its Stelara copycat and J&J's top product.
read more
By Robert King
The AHA wrote to the Justice Department seeking a new task force to investigate potential False Claims Act violations from Medicare Advantage plans.
read more
By Andrea Park
As it gears up to submit its noninvasive glucose monitoring technology for potential FDA clearance, Know Labs has recruited a pair of experts to its executive team to help smooth out the process.
read more
By Joseph Keenan
The shuttering of Teva’s long troubled manufacturing facility in Irvine, California, may create shortages of up to 24 generic sterile injectable drugs, including five essential medications of which the company supplied more than 15% of the market last year, according to an industry group.
read more
By Conor Hale
After securing targets in chronic kidney disease and idiopathic pulmonary fibrosis (IPF), AstraZeneca is collecting a second IPF target from its recently reupped collaboration with BenevolentAI.
read more
